Wexford-based Coeptis Therapeutics Holdings, a biopharmaceutical company focused on cell therapy platforms for cancer, autoimmune, and infectious diseases, recently launched Coeptis Technologies, a division aimed at diversifying and enhancing the company’s growth potential.
“We are embarking on an exciting journey of expansion that will not only enhance our presence in the biopharmaceutical sector but also venture into the high-growth technology sector,” Dave Mehalick, Coeptis Therapeutics president and CEO, said. “By establishing Coeptis Technologies, we are strategically positioning ourselves to leverage the unique opportunities present in these two dynamic industries. Our commitment to deliver unprecedented value to our shareholders is stronger than ever as we pursue innovative solutions that address the evolving needs of the market.”
The company has signed an agreement with Risk Mitigation Software Co., a data security software company, to acquire technology assets. The purchase will allow the company to enter the data security market and maximize shareholder value. Under the agreement, Risk Mitigation Software will transfer of their proprietary technologies to Coeptis Technologies.
The purchase is subject to customary closing conditions and is expected to close early next year.
Upon closing, Risk Mitigation Software’s president and CEO will join the Coeptis management team as head of Coeptis Technologies.